Regulatory T Cells: Barriers of Immune Infiltration Into the Tumor Microenvironment
- PMID: 34177968
- PMCID: PMC8222776
- DOI: 10.3389/fimmu.2021.702726
Regulatory T Cells: Barriers of Immune Infiltration Into the Tumor Microenvironment
Abstract
Regulatory T cells (Tregs) are key immunosuppressive cells that promote tumor growth by hindering the effector immune response. Tregs utilize multiple suppressive mechanisms to inhibit pro-inflammatory responses within the tumor microenvironment (TME) by inhibition of effector function and immune cell migration, secretion of inhibitory cytokines, metabolic disruption and promotion of metastasis. In turn, Tregs are being targeted in the clinic either alone or in combination with other immunotherapies, in efforts to overcome the immunosuppressive TME and increase anti-tumor effects. However, it is now appreciated that Tregs not only suppress cells intratumorally via direct engagement, but also serve as key interactors in the peritumor, stroma, vasculature and lymphatics to limit anti-tumor immune responses prior to tumor infiltration. We will review the suppressive mechanisms that Tregs utilize to alter immune and non-immune cells outside and within the TME and discuss how these mechanisms collectively allow Tregs to create and promote a physical and biological barrier, resulting in an immune-excluded or limited tumor microenvironment.
Keywords: cancer; immune infiltration; regulatory T cells (Treg); stroma; tumor microenvironment; vasculature.
Copyright © 2021 Scott, Gocher, Workman and Vignali.
Conflict of interest statement
DV: cofounder and stockholder – Novasenta, Tizona and Trishula; stockholder – Oncorus, Werewolf and Apeximmune; patents licensed and royalties - Astellas, BMS; scientific advisory board member - Tizona, Werewolf, F-Star, Bicara, Apeximmune; consultant - Astellas, BMS, Incyte, Almirall, G1 Therapeutics; research funding – Novasenta, BMS and Astellas. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures

Similar articles
-
Metabolic Regulation of Tregs in Cancer: Opportunities for Immunotherapy.Trends Cancer. 2017 Aug;3(8):583-592. doi: 10.1016/j.trecan.2017.06.005. Epub 2017 Jul 14. Trends Cancer. 2017. PMID: 28780935 Review.
-
Treg Fragility: A Prerequisite for Effective Antitumor Immunity?Cancer Immunol Res. 2018 Aug;6(8):882-887. doi: 10.1158/2326-6066.CIR-18-0066. Cancer Immunol Res. 2018. PMID: 30068755 Free PMC article. Review.
-
Induced regulatory T cells in inhibitory microenvironments created by cancer.Expert Opin Biol Ther. 2014 Oct;14(10):1411-25. doi: 10.1517/14712598.2014.927432. Epub 2014 Jun 17. Expert Opin Biol Ther. 2014. PMID: 24934899 Free PMC article. Review.
-
Immune checkpoint inhibitors in cancer therapy: a focus on T-regulatory cells.Immunol Cell Biol. 2018 Jan;96(1):21-33. doi: 10.1111/imcb.1003. Epub 2017 Nov 17. Immunol Cell Biol. 2018. PMID: 29359507 Review.
-
FoxP3+ T regulatory cells in cancer: Prognostic biomarkers and therapeutic targets.Cancer Lett. 2020 Oct 10;490:174-185. doi: 10.1016/j.canlet.2020.07.022. Epub 2020 Jul 25. Cancer Lett. 2020. PMID: 32721551 Review.
Cited by
-
Construction and comprehensive analysis of a novel prognostic signature associated with pyroptosis molecular subtypes in patients with pancreatic adenocarcinoma.Front Immunol. 2023 Feb 3;14:1111494. doi: 10.3389/fimmu.2023.1111494. eCollection 2023. Front Immunol. 2023. PMID: 36817451 Free PMC article.
-
Nature vs. Nurture: The Two Opposing Behaviors of Cytotoxic T Lymphocytes in the Tumor Microenvironment.Int J Mol Sci. 2021 Oct 18;22(20):11221. doi: 10.3390/ijms222011221. Int J Mol Sci. 2021. PMID: 34681881 Free PMC article. Review.
-
Genome, Metabolism, or Immunity: Which Is the Primary Decider of Pancreatic Cancer Fate through Non-Apoptotic Cell Death?Biomedicines. 2023 Oct 14;11(10):2792. doi: 10.3390/biomedicines11102792. Biomedicines. 2023. PMID: 37893166 Free PMC article. Review.
-
Natural killer cells for pancreatic cancer immunotherapy: Role of nanoparticles.Cancer Lett. 2023 Nov 28;579:216462. doi: 10.1016/j.canlet.2023.216462. Epub 2023 Nov 2. Cancer Lett. 2023. PMID: 37924937 Free PMC article.
-
Regulating the regulatory T cells as cell therapies in autoimmunity and cancer.Front Med (Lausanne). 2023 Sep 27;10:1244298. doi: 10.3389/fmed.2023.1244298. eCollection 2023. Front Med (Lausanne). 2023. PMID: 37828948 Free PMC article. Review.
References
-
- Solis-Castillo LA, Garcia-Romo GS, Diaz-Rodriguez A, Reyes-Hernandez D, Tellez-Rivera E, Rosales-Garcia VH, et al. . Tumor-Infiltrating Regulatory T Cells, CD8/Treg Ratio, and Cancer Stem Cells Are Correlated With Lymph Node Metastasis in Patients With Early Breast Cancer. Breast Cancer (2020) 27:837–49. 10.1007/s12282-020-01079-y - DOI - PubMed
-
- Shimizu J, Yamazaki S, Sakaguchi S. Induction of Tumor Immunity by Removing CD25+CD4+ T Cells: A Common Basis Between Tumor Immunity and Autoimmunity. J Immunol (1999) 163:5211–8. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources